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CPX-351, a dual-drug liposomal encapsulation of daunorubicin/cytarabine in a synergistic
1:5 molar ratio, is approved for the treatment of adults with newly diagnosed, therapy-
related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes
(AML-MRC). In a pivotal phase 3 study, patients aged 60 to 75 years with newly diagnosed,
high-risk/secondary AML were randomized to receive CPX-351 or conventional 713
chemotherapy. In the primary endpoint analysis, CPX-351 demonstrated significantly
prolonged median overall survival (OS) vs 713. These exploratory post hoc subgroup
analyses evaluated the impact of achieving complete remission (CR) or CR with incomplete
neutrophil or platelet recovery (CRi) with CPX-351 (73/153 [48%]) vs conventional 713 (52/56
[33%]) on outcomes. CPX-351 improved median OS vs 713 in patients who achieved CR or
CRi (25.43 vs 10.41 months; hazard ratio 5 0.49; 95% confidence interval, 0.31, 0.77).
Improved median OS was seen across AML subtypes (t-AML, AML-MRC), age subgroups (60
to 69 vs 70 to 75 years), patients with prior hypomethylating agent exposure, and patients
who did not undergo transplantation. Patients who achieved CR or CRi with CPX-351 also
had a higher rate of transplantation, a longer median OS landmarked from the date of
transplantation (not reached vs 11.65 months; hazard ratio5 0.43; 95% confidence interval,
0.21, 0.89), and a safety profile that was consistent with the known safety profile of 713.
These results suggest deeper remissions may be achieved with CPX-351, leading to improved
OS. This study was registered at www.clinicaltrials.gov as #NCT01696084.
Introduction
Secondary acute myeloid leukemia (sAML), which generally refers to the development of acute myeloid
leukemia (AML) following a prior myeloid malignancy or as a late complication of chemotherapy or
ionizing radiation (therapy-related acute myeloid leukemia [t-AML]),1,2 is historically associated with
poorer outcomes with conventional induction chemotherapy when compared with other AML
subtypes.3-10
CPX-351 (United States: Vyxeos, daunorubicin and cytarabine liposome for injection; Europe: Vyxeos
Liposomal, liposomal daunorubicin and cytarabine powder for concentrate for solution for infusion) is
Submitted 30 September 2020; accepted 8 February 2021; published online 16
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Relevant data are provided within this manuscript and supporting files, or within the files
for the primary study publication by Lancet et al.18 For data sharing, please contact the
corresponding author at tlin@kumc.edu.
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a dual-drug liposomal encapsulation of daunorubicin and cytarabine
approved by the US Food and Drug Administration and the
European Medicines Agency for the treatment of adults with newly
diagnosed t-AML or AML with myelodysplasia-related changes
(AML-MRC).11,12 CPX-351 was designed to improve efficacy vs
conventional chemotherapy through the coencapsulation of dau-
norubicin and cytarabine at a synergistic 1:5 molar ratio within
a bilayer liposome.13 Unlike conventional chemotherapy, the CPX-
351 liposome is maintained in human plasma for up to 24 hours,
with detectable drug present .7 days postadministration.14,15 The
CPX-351 liposome also enables intracellular delivery of the
synergistic drug ratio and enhances uptake in leukemia cells to
a greater extent than normal cells in the bone marrow.16,17 In the
primary analysis of data from the pivotal randomized phase 3 study
in older adults with newly diagnosed high-risk/sAML, induction
followed by consolidation with CPX-351 demonstrated a signifi-
cantly improved median overall survival (OS [primary endpoint];
9.56 vs 5.95 months; hazard ratio [HR] 5 0.69; 95% confidence
interval [CI], 0.52, 0.90; 1-sided P 5 .003) and a higher rate of
complete remission (CR) or CR with incomplete neutrophil or
platelet recovery (CRi) vs conventional 713 (48% vs 33%; 2-sided
P 5 .016), with a safety profile that was consistent with the known
safety profile of 713.18 After 5 years of follow-up, survival benefit
was maintained.19
Unfortunately, remission achieved with conventional chemotherapy
in sAML is less durable than in de novo AML. This was shown in
a large registry study that found patients with either an antecedent
hematologic disorder or t-AML who achieved CR with conventional
chemotherapy had significantly shorter OS landmarked from the
time of CR compared with de novo AML, irrespective of cytogenetic
risk group.20 It is not known whether achievement of remission with
newer agents, such as CPX-351, will translate into a similar benefit
in outcomes as conventional chemotherapy or if the differences
in the design and pharmacokinetic properties of CPX-351 may
translate into deeper remissions and improved outcomes in those
who achieve remission. Therefore, exploratory post hoc subgroup
analyses of the CPX-351 pivotal phase 3 study were performed
to explore the impact of achieving remission with CPX-351 vs
conventional 713 on survival, hematopoietic cell transplantation




In this open-label, controlled, multicenter, phase 3 trial (ClinicalTrials.
gov Identifier: #NCT01696084), patients were randomized 1:1 to
receive induction therapy with CPX-351 or 713 chemotherapy, as
described previously.18 Patients could receive up to 2 cycles of
induction with CPX-351 100 units/m2 (daunorubicin 44 mg/m2 plus
cytarabine 100 mg/m2) administered as a 90-minute infusion
on days 1, 3, and 5 (days 1 and 3 for second induction) or with
a 713 regimen consisting of cytarabine 100 mg/m2 per day
continuous infusion for 7 days (5 days for second induction) plus
daunorubicin 60 mg/m2 on days 1, 2, and 3 (days 1 and 2 for
second induction). A second induction was highly recommended
for any patient with documented reduction in leukemia burden and
was mandatory for patients achieving .50% reduction in blast
count at day 14. Patients who were not expected to receive second
induction included those with evidence of aplasia/hypoplasia (,5%
blast count) or equivocal bone marrow assessments.
Patients who achieved CR or CRi could receive up to 2 cycles of
consolidation with CPX-351 65 units/m2 (daunorubicin 29 mg/m2
plus cytarabine 65 mg/m2) administered as a 90-minute infusion
on days 1 and 3 or with the 512 regimen, consisting of cytarabine
100 mg/m2 per day continuous infusion for 5 days plus daunorubicin
60 mg/m2 on days 1 and 2. Patients could receive HCT at the
discretion of the treating physician.
This study was conducted in accordance with the principles of the
Declaration of Helsinki and the International Conference on
Harmonization Good Clinical Practice guidelines. The study
protocol and all modifications were approved by the institutional
review board or independent ethics committee at each study
site, and all patients provided written informed consent prior to
study participation.
Eligibility criteria
Study eligibility criteria have been described in detail elsewhere.18
Briefly, patients were aged 60 to 75 years with a pathological
diagnosis of AML according to World Health Organization 2008
criteria ($20% blasts in peripheral blood or bone marrow) and high-
risk/sAML based on prior cytotoxic treatment, history of myelodys-
plastic syndrome (MDS; with or without prior hypomethylating
agents [HMAs]) or chronic myelomonocytic leukemia (CMML), or
de novo AML with myelodysplasia-related cytogenetic abnormal-
ities. Key exclusion criteria included acute promyelocytic leukemia
t(15;17) or other favorable cytogenetics at screening, prior
induction therapy for AML (except hydroxyurea), active second-
ary malignancy or central nervous system leukemia, history of
myeloproliferative neoplasms other than CMML, or AML-MRC with
only morphologic evidence of multilineage dysplasia.
Endpoints and assessments
The primary study endpoint, OS, has been reported previously.18
Secondary efficacy endpoints included remission rate (CR,
CR1CRi; assessed according to the Revised International Working
Group Criteria for AML21) and remission duration. The proportion of
patients who underwent HCT was also evaluated. Safety outcomes
included adverse events and laboratory assessments.
Patients enrolled in the phase 3 study who achieved CR or CRi
during the study were included in these exploratory post hoc
subgroup analyses. Among patients who achieved CR or CRi,
further exploratory analyses were performed for the subgroups of
patients with t-AML, AML-MRC, and prior HMA exposure, as well
as by age (60 to 69 vs 70 to 75 years) and among those who did
not proceed to HCT.
Statistical analyses
The efficacy and safety exploratory post hoc analyses described
herein were performed in the subset of patients who achieved CR
or CRi during the study.
Statistical methodology has been described previously.18 Briefly,
time-to-event endpoints were assessed using a stratified log-rank
test to compare treatment groups. The Kaplan-Meier method was
used to estimate the distribution of these endpoints over time. HRs
and 95% CIs were estimated using a Cox proportional hazards
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regression model. Remission rates and other binary measures were
compared using a Mantel-Haenszel test.
Results
Patients
A total of 309 patients were randomized to treatment with CPX-351
(n5 153) or 713 (n5 156). Of these patients, 73 (48%) achieved
CR1CRi with CPX-351 and 52 (33%) achieved CR1CRi with
713 (odds ratio [OR] 5 1.77; 95% CI, 1.11, 2.81) and were
included in this analysis, including 57 (37%) vs 40 (26%) who
achieved a CR (OR 5 1.69; 95% CI, 1.03, 2.78; Table 1). Higher
rates of CR1CRi were achieved with CPX-351 vs 713 among the
subgroup of patients with t-AML (47% vs 36%) and also the
subgroup with AML-MRC (48% vs 33%).
Among patients who received only 1 induction cycle, CR1CRi
rates were 55% (58/105) with CPX-351 vs 34% (34/100) with
713, including CR rates of 45% (47/105) with CPX-351 vs 28%
(28/100) with 713. On the other hand, for patients who received 2
induction cycles, CR1CRi rates were 31% (15/48) with CPX-351
vs 35% (18/51) with 713, including CR rates of 21% (10/48) with
CPX-351 vs 24% (12/51) with 713. In a multivariate analysis,
karyotype (favorable/intermediate vs unfavorable; OR 5 3.95; 95%
CI, 2.12, 7.37; nominal P , .001), white blood cell count (,203
103/mL vs$203 103/mL; OR5 3.48; 95%CI, 1.47, 8.22; nominal
P5 .005), and treatment arm (CPX-351 vs 713; OR5 1.85; 95%
CI, 1.12, 3.08; nominal P 5 .017) were associated with
achievement of CR or CRi. Furthermore, although karyotype, sex,
white blood cell count, and treatment arm were associated with
achievement of CR, only karyotype was associated with achieve-
ment of CRi (supplemental Table 1).
Baseline characteristics for all patients who achieved CR, CRi, and
CR or CRi were generally balanced between CPX-351 and 713
treatment arms (Table 2). Although randomization into the study
was stratified for sAML subtype, the treatment groups were not
necessarily still balanced for sAML subtype among patients who
achieved CR or CRi. Fewer patients with t-AML who achieved CR
or CRi after CPX-351 vs 713 had received prior nonanthracycline
chemotherapy alone (n5 2/14 [14%] vs n5 5/12 [42%]), whereas
prior radiation therapy alone was less frequent in patients receiving
713 (n 5 5/14 [36%] vs n 5 2/12 [17%]). Among patients with
AML-MRC who achieved CR or CRi, fewer patients receiving
CPX-351 vs 713 had antecedent MDS with prior HMAs (n5 18/59
[31%] vs n5 18/40 [45%]), and more patients receiving CPX-351
had de novo AML with MDS karyotype (n 5 23/59 [39%] vs
n 5 12/40 [30%]).
Duration of remission and relapse-free survival
For all patients with CR or CRi, the median duration of remission
was 6.93 months with CPX-351 vs 6.11 months with 713
(HR 5 0.77; 95% CI, 0.47, 1.26). Among patients who achieved
CR, the median duration of remission was 7.89 vs 6.54 months
(HR5 0.90; 95% CI, 0.54, 1.49), and among patients who achieved
CRi, the median duration of remission was 5.32 vs 3.09 months
(HR 5 0.46; 95% CI, 0.17, 1.20).
Among patients who achieved CR, median relapse-free survival
was also longer with CPX-351 vs 713 (11.24 vs 8.82 months;
HR 5 0.65; 95% CI, 0.39, 1.06).
Table 1. CR and CR1CRi rates and postremission consolidation
cycles by patient subgroup
Characteristic, n (%) CPX-351 713* OR (95% CI)
Total study population 153 156
CR1CRi 73 (48) 52 (33) 1.77 (1.11, 2.81)
CR 57 (37) 40 (26) 1.69 (1.03, 2.78)
Number of consolidation cycles 73 52
0 25 (34) 20 (38)
1 25 (34) 20 (38)
2 23 (32) 12 (23)
t-AML 30 33
CR1CRi 14 (47) 12 (36) 1.53 (0.56, 4.20)
CR 11 (37) 10 (30) 1.33 (0.47, 3.81)
Number of consolidation cycles 14 12
0 4 (29) 5 (42)
1 4 (29) 5 (42)
2 6 (43) 2 (17)
AML-MRC 123 123
CR1CRi 59 (48) 40 (33) 1.83 (1.09, 3.09)
CR 46 (37) 30 (24) 1.80 (1.02, 3.17)
Number of consolidation cycles 59 40
0 21 (36) 15 (38)
1 21 (36) 15 (38)
2 17 (29) 10 (25)
Prior HMA exposure† 62 71
CR1CRi 23 (37) 20 (28) 1.50 (0.73, 3.12)
CR 16 (26) 11 (15) 1.90 (0.80, 4.48)
Number of consolidation cycles 23 20
0 11 (48) 9 (45)
1 6 (26) 6 (30)
2 6 (26) 5 (25)
Ages 60 to 69 y 96 102
CR1CRi 48 (50) 37 (36) 1.76 (1.00, 3.10)
CR 38 (40) 27 (26) 1.82 (1.00, 3.32)
Number of consolidation cycles 48 37
0 18 (38) 17 (46)
1 16 (33) 14 (38)
2 14 (29) 6 (16)
Ages 70 to 75 y 57 54
CR1CRi 25 (44) 15 (28) 2.03 (0.92, 4.49)
CR 19 (33) 13 (24) 1.58 (0.69, 3.62)
Number of consolidation cycles 25 15
0 7 (28) 3 (20)
1 9 (36) 6 (40)
2 9 (36) 6 (40)
*Patients in the 713 arm received consolidation with cytarabine and daunorubicin on
a 512 schedule.
†Includes patients in the prespecified randomization strata of antecedent MDS with prior
HMA exposure, as well as patients in other strata (eg, t- AML, antecedent CMML) who had
previously received HMAs.
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OS
Median OS was longer with CPX-351 vs 713 in patients who
achieved CR or CRi (25.43 vs 10.41 months; HR 5 0.49; 95% CI,
0.31, 0.77; Figure 1A). Median OS was longer with CPX-351 vs
713 both in patients who achieved CR (25.43 months [n 5 57] vs
10.97 months [n 5 40]; HR 5 0.49; 95% CI, 0.29, 0.83) and in
those who achieved CRi (13.70 months [n 5 16] vs 8.97 months
[n5 12]; HR5 0.48; 95% CI, 0.19, 1.26). In a multivariate analysis,
karyotype (favorable/intermediate vs unfavorable; HR 5 0.48; 95%
CI, 0.30, 0.79; nominal P5 .003), platelet count (#503103/mL vs
.503 103/mL; HR5 1.83; 95%CI, 1.11, 3.01; nominal P5 .017),
and treatment arm (CPX-351 vs 713; HR 5 0.40; 95% CI, 0.25,
0.65; nominal P , .001) were associated with OS among patients
who achieved CR or CRi (supplemental Table 2).
In addition, among patients who achieved CR or CRi, median OS
was numerically longer with CPX-351 vs 713 overall (Figure 1A)
and in subgroups of patients with t-AML, with AML-MRC, and
ages 60 to 69 and 70 to 75 years (Figure 1B-F), with the most
notable improvements in OS observed among patients with
t-AML (not reached vs 9.15 months; HR 5 0.21; 95% CI, 0.07,
0.68; Figure 1B) and those aged 70 to 75 years (25.43 vs 8.41
months; HR 5 0.30; 95% CI, 0.13, 0.65; Figure 1F). However, it
Table 2. Baseline characteristics of patients who achieved CR or CRi
Achieved CR or CRi Achieved CR Achieved CRi
CPX-351 713 CPX-351 713 CPX-351 713
Characteristic, n (%) (n 5 73) (n 5 52) (n 5 57) (n 5 40) (n 5 16) (n 5 12)
Age
60 to 69 y 48 (66) 37 (71) 38 (67) 27 (68) 10 (63) 10 (83)
70 to 75 y 25 (34) 15 (29) 19 (33) 13 (33) 6 (38) 2 (17)
Male 45 (62) 25 (48) 34 (60) 19 (48) 11 (69) 6 (50)
ECOG PS
0 20 (27) 20 (38) 17 (30) 17 (43) 3 (19) 3 (25)
1 48 (66) 26 (50) 35 (61) 19 (48) 13 (81) 7 (58)
2 5 (7) 6 (12) 5 (9) 4 (10) 0 2 (17)
AML subtype
t-AML 14 (19) 12 (23) 11 (19) 10 (25) 3 (19) 2 (17)
Antecedent MDS with prior HMA* 18 (25) 18 (35) 13 (23) 10 (25) 5 (31) 8 (67)
Antecedent MDS without prior HMA* 14 (19) 7 (13) 12 (21) 7 (18) 2 (13) 0
Antecedent CMML* 4 (5) 3 (6) 2 (4) 3 (8) 2 (13) 0
De novo AML with MDS karyotype* 23 (32) 12 (23) 19 (33) 10 (25) 4 (25) 2 (17)
Prior HMA therapy† 23 20 16 11 7 9
Azacitidine only 18 (78) 13 (65) 13 (81) 8 (73) 5 (71) 5 (56)
Decitabine only 4 (17) 5 (25) 3 (19) 3 (27) 1 (14) 2 (22)
Azacitidine and decitabine 1 (4) 2 (10) 0 0 1 (14) 2 (22)
Median duration of prior HMA therapy (range), d 120 (22, 1644) 126 (6, 761) 130.5 (22, 1644) 95 (6, 761) 113 (28, 307) 185 (53, 320)
Bone marrow blast (aspirate) percentage‡ 68 48 53 37 15 11
Median (range) 33 (5, 80) 30.5 (6, 77) 35 (5, 80) 32 (6, 77) 27 (8, 75) 29 (12, 60)
Cytogenetic risk by NCCN
Favorable/intermediate 39/70 (56) 30/48 (63) 30/55 (55) 21/36 (58) 9/15 (60) 9/12 (75)
Unfavorable 31/70 (44) 18/48 (38) 25/55 (45) 15/36 (42) 6/15 (40) 3/12 (25)
FLT3 mutation 15/68 (22) 5/44 (11) 12/53 (23) 4/34 (12) 3/15 (20) 1/10 (10)
WBC count
,203 103/mL 68/73 (93) 47/51 (92) 52/57 (91) 36/39 (92) 16/16 (100) 11/12 (92)
$203 103/mL 5/73 (7) 4/51 (8) 5/57 (9) 3/39 (8) 0/16 (0) 1/12 (8)
Platelet count
#503 103/mL 43/73 (59) 25/51 (49) 34/57 (60) 17/39 (44) 9/16 (56) 8/12 (67)
.503 103/mL 30/73 (41) 26/51 (51) 23/57 (40) 22/39 (56) 7/16 (44) 4/12 (33)
ECOG PS, Eastern Cooperative Oncology Group performance status; FLT3, fms-like tyrosine kinase 3; NCCN, National Comprehensive Cancer Network; WBC, white blood cell.
*Subgroup of patients with AML-MRC.
†Includes patients in the prespecified randomization strata of antecedent MDS with prior HMA exposure, as well as patients in other strata (eg, t- AML, antecedent CMML) who had
previously received HMAs.
‡Pathological diagnosis of AML was according to 2008 World Health Organization criteria (ie, $20% blasts in the peripheral blood or bone marrow) and confirmed by an independent
pathologist.
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Figure 1. OS in patients who achieved CR or
CRi. Among patients who achieved CR or CRi,
median OS was numerically longer with CPX-351
vs 713 overall (A) and generally across the
evaluated subgroups of patients (B-G). KM,
Kaplan-Meier; NE, not estimable.
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should be noted that the number of patients in some subgroups
was small.
Among patients who achieved CR or CRi and did not undergo
HCT (CPX-351: n 5 33; 713: n 5 28), median OS was numeri-
cally longer with CPX-351 vs 713 (14.72 vs 7.59months; HR5 0.57;
95% CI, 0.31, 1.03; Figure 1G). Within this subgroup, median
OS was 15.74 months with CPX-351 vs 7.36 months with 713
(HR 5 0.53; 95% CI, 0.23, 1.22) among patients aged 60 to
69 years and was 12.19 months vs 8.41 months (HR 5 0.47; 95%
CI, 0.19, 1.21) among patients aged 70 to 75 years. Median OS
was numerically longer with CPX-351 vs 713 both in patients who
achieved CR and did not undergo HCT (19.15 months [n 5 27] vs
8.41 months [n5 21]; HR5 0.55; 95%CI, 0.27, 1.10) and in those
who achieved CRi and did not undergo HCT (8.54 months [n 5 6]
vs 5.13 months [n 5 7]; HR 5 0.61; 95% CI, 0.18, 2.03). Of note,
the majority of patients who achieved CR or CRi but did not
undergo HCT received postremission consolidation in both the
CPX-351 (1 cycle: 8/33 [24%]; 2 cycles: 16/33 [48%]) and 713
(1 cycle: 13/28 [46%]; 2 cycles: 7/28 [25%]) treatment arms; for
these patients, median OS was 13.67 months with CPX-351 vs
8.44 months with 713 (HR 5 0.62; 95% CI, 0.31, 1.26). The
remaining patients who achieved CR or CRi but did not receive
consolidation or proceed to HCT discontinued treatment (CPX-
351: n 5 6; 713: n 5 4), relapsed (CPX-351: n 5 2; 713: n 5 4),
or did not receive further treatment per their physician’s choice
(CPX-351: n 5 1; 713: n 5 0).
HCT outcomes
Fifty-two (34%) of 153 patients receiving CPX-351 and 39 (25%)
of 156 patients receiving 713 underwent HCT in this study. Most
patients who underwent HCT were in CR or CRi in both the CPX-
351 arm (CR: 30/52 [58%]; CRi: 10/52 [19%]) and the 713 arm
(19/39 [49%]; 5/39 [13%]).18 Among patients who achieved CR or
CRi, the HCT rate was numerically higher with CPX-351 vs 713
(40/73 [55%] vs 24/52 [46%]; OR, 0.71; 95% CI, 0.35, 1.44). The
HCT rate with CPX-351 vs 713 was 53% (30/57) vs 48% (19/40)
in patients who achieved CR and 63% (10/16) vs 42% (5/12) in
patients who achieved CRi. Among patients who achieved CR or
CRi, the HCT rate was numerically higher with CPX-351 vs 713 in
all evaluated subgroups except for patients with t-AML (supple-
mental Table 3). Postremission consolidation prior to HCT was
common in both treatment arms: among patients who proceeded to
HCT, 60% of patients in the CPX-351 arm received consolidation
prior to their HCT (1 cycle: 17/40 [43%]; 2 cycles: 7/40 [18%])
compared with 50% in the 713 arm (1 cycle: 7/24 [29%]; 2 cycles:
5/24 [21%]).
Overall, median OS landmarked from the date of HCT was
numerically longer with CPX-351 vs 713 in patients who achieved
CR or CRi (not reached vs 11.65 months; HR 5 0.43; 95% CI,
0.21, 0.89; Figure 2A). Median OS landmarked from the date of
HCT with CPX-351 vs 713 was not reached vs 10.25 months
in patients who achieved CR (HR 5 0.43; 95% CI, 0.19, 0.96)
and not reached vs 14.09 months in patients who achieved CRi
(HR 5 0.43; 95% CI, 0.09, 2.13). Median OS landmarked from the
date of HCT was numerically longer with CPX-351 vs 713 in the
evaluated subgroups of patients (Figure 2B-F), most notably those
with t-AML (not reached vs 6.60 months; HR5 0.10; 95%CI, 0.01,
0.84; Figure 2B) and those aged 70 to 75 years (not reached vs
4.14 months; HR5 0.09; 95%CI, 0.02, 0.53; Figure 2F). However,
it should be noted that the number of patients in some of the
evaluated subgroups was small.
Safety and tolerability
The safety profile of CPX-351 in patients who achieved CR or CRi
was generally consistent with the overall study population and the
known safety profile of 713 (Table 3). In patients who achieved CR
or CRi, the most frequently reported grade 3 to 5 treatment-
emergent adverse events (TEAEs; $10% of patients) at any time
during the study were febrile neutropenia (CPX-351: 79% vs 713:
77%), hypertension (14% vs 6%), pneumonia (12% vs 15%),
bacteremia (11% vs 2%), sepsis (6% vs 10%), and pulmonary
edema (3% vs 10%). Febrile neutropenia (CPX-351: 15% vs 713:
12%) was the most frequently reported serious TEAE. Only 1
patient experienced discontinuation because of a TEAE in the
CPX-351 arm (cardiac failure).
Four patients who achieved CR or CRi died during the
postremission phase because of the following causes: sepsis
(CPX-351), atrial fibrillation (713), disease progression (713),
and intracranial hemorrhage (713). No patient experienced
early mortality (within 60 days of treatment initiation) in either
treatment arm.
CPX-351 was associated with a longer median time to recovery of
neutrophils and platelets vs 713 in all patients who achieved CR or
CRi (Table 4). Similar results were observed for the subgroups of
patients with t-AML, AML-MRC, and prior HMA exposure, as well as
by age subgroups.
Discussion
CPX-351 is a dual-drug liposomal encapsulation of daunorubicin
and cytarabine at a synergistic 1:5 molar ratio14 that has shown
significantly improved survival, higher remission rates, and compa-
rable safety to that of the conventional 713 regimen in older
patients with high-risk/sAML in a large, multicenter, randomized,
controlled, phase 3 trial.18 Consistent with these findings, results
from these exploratory post hoc subgroup analyses demonstrated
that, among the overall group of patients who achieved remission,
CPX-351 improved median OS and the likelihood of proceeding to
HCT vs 713, suggesting the potential for achievement of deeper
responses with CPX-351, although this hypothesis needs to be
confirmed in a subsequent study. Furthermore, median OS was
numerically longer with CPX-351 vs 713 in subgroups of patients
with t-AML and AML-MRC, as well as by age subgroups and among
patients who did not undergo HCT, although the most notable
improvements in OS were observed for those with t-AML and
among older patients (aged 70 to 75 years). However, the ability to
form definitive conclusions based on these data is limited by the
small number of patients in some subgroups.
The assessment of measurable residual disease (MRD) in patients
with AML who achieve remission provides powerful prognostic
information. Unfortunately, the assessment of MRD was not
prospectively collected in this study, and there are insufficient
banked patient samples to assess MRD. Although MRD results are
not available from this phase 3 study, the hypothesis of deeper
remissions achieved with CPX-351 vs 713 is suggested by studies
of real-world evidence with CPX-351 that have reported notable
proportions of responders achieving MRD negativity. A compas-
sionate use program from 33 centers in Italy evaluated the clinical
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activity of CPX-351 in patients with t-AML or AML-MRC in a real-life
setting. Results from this study indicated a CR1CRi rate of 65% in
71 evaluable patients after cycle 1, with 70% achieving CR by the
end of treatment. MRD was assessed with multicolor flow cytometry
(negativity defined as ,0.01%) and/or Wilms tumor (WT1) gene
expression levels. Following the first induction, multicolor flow
cytometry MRD negativity was achieved in 15/40 (38%) assessed
patients, whereas WT1 MRD negativity was achieved in 21/38
(55%) assessed patients.22 A multicenter, retrospective study
























































































































































































































































































































Figure 2. OS landmarked from the HCT date in patients who achieved CR or CRi. Among patients who achieved CR or CRi and subsequently underwent HCT,
median OS landmarked from the HCT date was numerically longer with CPX-351 vs 713 overall (A) and across the evaluated subgroups of patients (B-F).
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t-AML or AML-MRC from 12 centers in France. CR1CRi was
achieved by 61/103 (59%) patients, including 57 (55%) with CR.
MRD negativity at the 1023 sensitivity threshold (assessed with flow
cytometry, next-generation sequencing, or real-time quantitative
polymerase chain reaction) was achieved in 16/28 (57%) responders
with an MRD evaluation at the first consolidation cycle.23 In another
multicenter, retrospective study that evaluated the efficacy of CPX-
351 in patients who primarily had t-AML or AML-MRC, CR1CRi was
achieved by 41/66 (62%) patients with wild-type TP53, including 30
(45%) with CR. Among patients with wild-type TP53 who achieved
CR, MRD negativity was reported for 9/25 (36%) patients with an
MRD evaluation.24 However, it should be noted that these studies
were not designed to compare outcomes observed for CPX-351
with conventional chemotherapy, and it will be important to include
MRD assessments in future clinical studies of CPX-351.
The achievement of deep remissions with CPX-351 is important,
as historically remission alone did not necessarily translate into
a survival benefit, and survival rates remain low among sAML
patients who achieve remission with conventional chemotherapy.20
Results of the current study demonstrated that, compared with
conventional 713 chemotherapy, CPX-351 not only improves
remission rates in patients with high-risk/sAML but also survival
outcomes among those who achieved CR or CRi. Key differences
between the CPX-351 liposome and conventional 713 chemo-
therapy include the prolonged and coordinated pharmacokinetics of
daunorubicin and cytarabine with the CPX-351 liposome14 and
persistent drug exposure at a synergistic ratio within the bone
marrow.13 Furthermore, the CPX-351 liposome enables intracellu-
lar delivery with greater uptake in leukemic cells than normal cells in
the bone marrow.16,17
Allogeneic HCT is recommended as postremission therapy in order
to prolong remission and prevent recurrence in patients with AML25;
it is currently the most effective therapy with curative intent for
patients with intermediate- or poor-risk AML. Patients who achieved
CR or CRi with CPX-351 in this study were more likely to proceed
to HCT and had a longer median OS landmarked from the date of
HCT vs those who achieved remission with 713 chemotherapy,
suggesting CPX-351 is a viable option for patients in whom HCT
can be considered. Similar to findings for median OS, this
improvement in median OS landmarked from the date of HCT vs
713 was most notable for patients with t-AML, and among older
patients (aged 70 to 75 years) who achieved CR or CRi, and the
number of patients in some subgroups was small. We cannot be
certain whether the difference in number of second consolidation
cycles prior to HCT contributed to the more favorable post-HCT
survival observed with CPX-351, although this remains a possibility.
Table 3. Summary of TEAEs in patients who achieved CR or CRi
n (%) CPX-351 (n 5 73) 713 (n 5 52)
Any TEAE* 73 (100) 52 (100)
Febrile neutropenia 60 (82) 40 (77)
Nausea 38 (52) 28 (54)
Constipation 36 (49) 24 (46)
Peripheral edema 32 (44) 29 (56)
Decreased appetite 30 (41) 23 (44)
Fatigue 29 (40) 26 (50)
Rash 29 (40) 15 (29)
Diarrhea 28 (38) 38 (73)
Dyspnea 27 (37) 13 (25)
Epistaxis 25 (34) 11 (21)
Chills 23 (32) 20 (38)
Cough 23 (32) 15 (29)
Headache 22 (30) 18 (35)
Hypotension 20 (27) 13 (25)
Dizziness 19 (26) 19 (37)
Mucosal inflammation 19 (26) 9 (17)
Pyrexia 17 (23) 14 (27)
Insomnia 16 (22) 13 (25)
Pleural effusion 12 (16) 15 (29)
Any serious TEAE† 35 (48) 24 (46)
Febrile neutropenia 11 (15) 6 (12)
Acute respiratory failure 5 (7) 1 (2)
Ejection fraction decreased 4 (5) 2 (4)
Sepsis 4 (5) 2 (4)
Pneumonia 2 (3) 3 (6)
Pulmonary edema 1 (1) 3 (6)
Grade 5 TEAE 1 (1) 3 (6)
Discontinuation due to TEAE 1 (1) 0
*List of individual TEAEs includes all TEAEs occurring in $25% of patients in either
treatment arm.
†List of individual TEAEs includes all serious TEAEs occurring in $5% of patients in
either treatment arm.
Table 4. Median time to neutrophil and platelet recovery from treatment initiation of the last induction in patients who achieved CR or CRi
1 induction cycle 2 induction cycles
CPX-351 713 CPX-351 713
CR1CRi, n 58 34 15 18
Median (IQR) time to ANC recovery$0.53 103 neutrophils/mL, d 35 (29, 41) 29 (28, 35) 35 (28, 44) 28 (22, 29)
Median (IQR) time to platelet recovery $503 103 platelets/mL, d 36.5 (29, 43)* 29 (27, 36)* 35 (28, 48)† 24 (21, 29)†
CR, n 47 28 10 12
Median (IQR) time to ANC recovery $1 3 103 neutrophils/mL, d 37 (30, 42) 29 (28, 35) 34.5 (28, 42) 28 (24, 29.5)
Median (IQR) time to platelet recovery$1003 103 platelets/mL, d 40 (34, 47) 30 (28, 35.5) 35.5 (33, 42) 28.5 (22, 33.5)
ANC, absolute neutrophil count; IQR, interquartile range.
*Platelet recovery for patients achieving CR or CRi in 1 induction cycle was available for 56 patients in the CPX-351 arm and 32 patients in the 713 arm.
†Platelet recovery for patients achieving CR or CRi in 2 induction cycles was available for 14 patients in the CPX-351 arm and 17 patients in the 713 arm.
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It is also noteworthy that median OS was also longer with CPX-351
vs 713 among patients who achieved CR or CRi but did not
subsequently undergo HCT, suggesting a treatment benefit of
remission with CPX-351 even among patients who do not proceed
to HCT.
The CPX-351 safety profile in these subgroups was consistent with
the overall study population18 and known safety profile of 713. Of
note, as expected and observed in the overall study population,18
median time to recovery of neutrophils and platelets was longer with
CPX-351 vs 713 in all subgroups of patients; the prolonged
myelosuppression observed with CPX-351 may be attributed to the
prolonged drug exposure observed with CPX-351.14,15 Importantly,
despite prolonged myelosuppression, no patient experienced early
mortality (within 60 days of treatment initiation) in the CPX-351 arm.
In summary, CPX-351 has demonstrated longer median OS,
a higher rate of patients undergoing HCT, longer median OS
landmarked from the date of HCT, and comparable safety to that of
conventional 713 chemotherapy among patients who achieved CR
or CRi in this population of older adults with newly diagnosed high-
risk/sAML. Although it was not possible to evaluate the depth of
remission via MRD assessments, results of the current analyses
suggest the remissions achieved with CPX-351 treatment may
permit more patients to proceed to HCT and lead to prolonged
survival; however, this observation needs to be confirmed in
a subsequent study. Together, the findings from these subgroup
analyses build upon and further strengthen the improved outcomes
observed with CPX-351 vs 713 in the overall study population.
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